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A B S T R A C T 
Objective: There are currently no local data on 
the sperm retrieval and pregnancy rates in in-vitro 
fertilisation and testicular sperm extraction cycles, 
especially with regard to the presence of genetic 
abnormalities. This study aimed to determine the 
sperm retrieval and pregnancy rates in infertile couples 
who underwent in-vitro fertilisation and testicular 
sperm extraction for non-obstructive azoospermia. 
Methods: This retrospective case series was 
conducted at a tertiary assisted reproduction unit in 
Hong Kong. Men with non-obstructive azoospermia 
who underwent in-vitro fertilisation and testicular 
sperm extraction between January 2001 and 
December 2013 were included. The main outcome 
measures were sperm retrieval and pregnancy rates.
Results: During the study period, 89 men with 
non-obstructive azoospermia underwent in-vitro 
fertilisation and testicular sperm extraction. Sperm 
was successfully retrieved in 40 (44.9%) men. 
There was no statistically significant difference in 
the sperm retrieval rate of those with karyotypic 
abnormalities (2/5, 40.0% vs 28/61, 45.9%; P=1.000) 
and AZFc microdeletion (3/6, 50.0% vs 28/61, 45.9%; 
P=1.000) compared with those without. Sperms 
were successfully retrieved in patients who had 
mosaic Klinefelter syndrome (2/3, 66.7%) but not in 
the patient with non-mosaic Klinefelter syndrome. 
No sperms were found in men with AZFa or AZFb 
microdeletions. Pregnancy test was positive in 15 
(16.9%) patients and the clinical pregnancy rate was 
13.5% (12/89) per cycle. The clinical pregnancy rate 
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New knowledge added by this study
• Our study provides important local data for counselling of men with non-obstructive azoospermia. The sperm 
retrieval rate and clinical pregnancy rate per cycle in men undergoing in-vitro fertilisation and testicular sperm 
extraction in our unit were 44.9% and 13.5%, respectively.
• There was no statistically significant difference in the sperm retrieval and pregnancy rates in those with 
karyotypic abnormalities and AZFc microdeletion compared with those without. Sperms, however, were not 
found in men with AZFa or AZFb microdeletions.
Implications for clinical practice or policy
• Although karyotype abnormalities and AZFc microdeletion did not affect the sperm retrieval and pregnancy 
rates in couples undergoing in-vitro fertilisation and testicular sperm extraction, karyotype and Y-microdeletion 
should be checked in men with non-obstructive azoospermia. The risk of vertical transmission of genetic 
abnormalities should be discussed and couples should be offered appropriate genetic counselling before 
treatment.
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ORIGINAL ARTICLE
per transfer was 34.3% (12/35).
Conclusions: The sperm retrieval rate and clinical 
pregnancy rate per initiated cycle in men undergoing 
in-vitro fertilisation and testicular sperm extraction 
in our unit were 44.9% and 13.5%, respectively. No 
sperms could be retrieved in the presence of AZFa 
and AZFb microdeletions, but karyotype and AZFc 
microdeletion abnormalities otherwise did not 
predict the success of sperm retrieval in couples 
undergoing in-vitro fertilisation and testicular 
sperm extraction. Genetic tests are important prior 
to testicular sperm extraction for patient selection 
and genetic counselling.
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香港非梗阻性無精子症患者接受體外受精和睾丸
精子提取後的取精成功率和隨後的妊娠率
高嘉意、柴逸蘭、李芷茵、李幸奐、劉綺蘭、何崑崙、 
談寶雛、楊樹標、何柏松、吳鴻裕
目的：香港目前並沒有體外受精和睾丸精子提取（IVF-TESE）的本
地數據，尤其是與遺傳異常相關的資料。本研究旨在找出非梗阻性無
精子症（NOA）患者接受IVF-TESE後的取精成功率以及隨後的妊娠
率。
方法：本回顧性病例系列研究於香港一所三級輔助生育技術中心內
進行。研究對象為2001年1月至2013年12月期間曾接受IVF-TESE的
NOA患者。主要結果測量為參與者的取精成功率以及隨後的妊娠率。
結果：研究期間共89名NOA患者接受IVF-TESE。40案例成功提取精
子，成功率為44.9%。比較核型異常與正常的病例並無發現統計學顯
著差異（2/5，40.0%比28/61，45.9%；P=1.000）；Y染色體AZFc區
微缺失與沒有缺失的病例同樣並無統計學顯著差異（3/6，50.0%比
28/61，45.9%；P=1.000）。3例鑲嵌型Klinefelter症候群患者中2例
（66.7%）成功提取精子，但非鑲嵌型Klinefelter症候群患者則未能成
功。未有發現AZFa區和AZFb區微缺失患者有精子。15例（16.9%）成
功妊娠，周期臨床妊娠率為13.5%（12/89）。移植周期臨床妊娠率為
34.3%（12/35）。
結論：接受IVF-TESE的周期取精成功率為44.9%，周期妊娠率為
13.5%。AZFa區和AZFb區微缺失患者未能成功提取精子，但核型異常
及AZFc區微缺失並不能預測能否成功提取精子。IVF-TESE前進行基
因測試對於病例選擇及病人遺傳諮詢相當重要。
Introduction
Male-factor infertility is involved in about half of 
all infertile couples who seek assisted reproduction 
treatment.1 The advent of in-vitro fertilisation 
(IVF) with intracytoplasmic sperm injection (ICSI) 
has allowed many men with severe male factor to 
have their own genetic child.2 The development of 
surgical sperm retrieval techniques by testicular 
sperm extraction (TESE) has extended the possibility 
of fatherhood to those with non-obstructive 
azoospermia (NOA).3 
 The reported sperm retrieval rate from TESE 
varies in different studies due to inclusion of different 
populations, but is generally quoted to be around 
50%.4 Nevertheless TESE is invasive. In a recent 
retrospective cohort study by Vloeberghs et al,5 
only one (14.3%) out of seven men undergoing IVF-
TESE eventually became a biological father. Studies 
have also shown a high prevalence of chromosomal 
abnormalities and Y-microdeletion in infertile men 
with NOA or severe oligozoospermia.6-9 These 
genetic abnormalities can potentially be transmitted 
vertically resulting in a child with sex aneuploidies 
or boys with the same Y-microdeletion.10 Guidelines 
from the American Society for Reproductive 
Medicine, American Urological Association, 
Canadian Urological Association, and International 
Federation of Fertility Societies are unanimous in 
suggesting that all men with NOA due to testicular 
failure should be offered genetic testing to exclude 
chromosomal abnormalities and Y chromosome 
microdeletions, and that genetic counselling be 
offered if an abnormality is detected.11-14
 There are currently no local data on the sperm 
retrieval and pregnancy rates in IVF-TESE cycles, 
especially with regard to the presence of genetic 
abnormalities. Such information is invaluable to 
couples in pretreatment counselling and could affect 
their decision about treatment options. In this study, 
we determined the sperm retrieval and pregnancy 
rates in infertile couples who underwent IVF-TESE 
for NOA. 
Methods
The study was a retrospective analysis of couples 
who underwent the first IVF cycle and required 
TESE for NOA at Queen Mary Hospital, a university 
affiliated tertiary care hospital, from January 2001 
to December 2013. They were identified from our 
assisted reproductive technique database. Ethics 
approval was obtained from the Institutional Review 
Board of the University of Hong Kong / Hospital 
Authority Hong Kong West Cluster, with the 
requirement of patient informed consent waived 
because of its retrospective nature. 
 Husbands who attended our subfertility clinic 
were requested to submit one semen sample to the 
andrology laboratory of our centre prior to the first 
consultation. If the first semen analysis was abnormal, 
they were asked to submit a second semen sample. 
Semen analysis was based on the criteria of the 
World Health Organization (1999, 2010).15,16 Those 
with azoospermia confirmed in two semen samples 
following centrifugation were referred to the male 
infertility clinic for further assessment by urologists. 
All patients had detailed urological and reproductive 
history, physical examination, and hormonal 
profile including morning serum testosterone, 
follicle-stimulating hormone (FSH), and luteinising 
hormone.17 Men with azoospermia deemed to be due 
to a non-obstructive cause, as suggested by raised 
FSH and small testes, were advised to check their 
karyotype and microdeletion of the Y chromosome. 
The detailed techniques for chromosome analysis 
and Y-microdeletion studies by polymerase chain 
reaction of DNA from peripheral blood have been 
previously described.6,9,18 Karyotyping was performed 
by analysis of banded metaphase chromosomes 
from cultured cells. At least 15 and 30 metaphases 
were analysed routinely and whenever an anomaly 
was suspected, respectively.6 Y-microdeletion was 
analysed using six Y chromosome specific sequence 
tagged site markers that corresponded to the AZFa 
(sY84, sY86), AZFb (sY127, sY132), and AZFc (SY254, 
sY255) regions.6,9,18 Information on karyotype and 
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Y-microdeletion was obtained from the medical 
record of the patients, and cross-referenced with the 
database of the genetic screening for male subfertility 
at Tsan Yuk Hospital. 
 Men with NOA who wished to have their own 
genetic child would be advised to undergo TESE 
to retrieve sperms. The most common ovarian 
stimulation protocols used in our unit were the long 
gonadotropin-releasing hormone (GnRH) agonist 
and GnRH antagonist protocols. Details of the 
stimulation cycle have previously been described.19 
Patients attended the clinic on day 2 of the treatment 
cycle. Transvaginal ultrasonography was performed 
to determine antral follicle count (AFC) and serum 
oestradiol level was checked. Ovarian stimulation 
was commenced if the serum oestradiol level was 
confirmed at basal level and there was no ovarian 
cyst. The gonadotropin dosage depended on the 
woman’s age, AFC, and previous ovarian response. 
Transvaginal ultrasound for follicular tracking 
was performed 7 days after the start of ovarian 
stimulation and every 1 to 3 days thereafter. Further 
dosage of gonadotropins was titrated depending on 
the ovarian response of the patient during follicular 
tracking. Human chorionic gonadotropin (hCG) 
was given to trigger final oocyte maturation when 
the mean diameter of the leading follicle was at 
least 18 mm and three or more follicles reached a 
mean diameter of at least 16 mm. Transvaginal 
ultrasound-guided oocyte retrieval was performed 
34 to 36 hours later. 
 The urologist was responsible for performing 
TESE that was performed under general anaesthesia 
on the day of oocyte retrieval. In conventional TESE, 
the scrotal skin and tunica vaginalis were opened and 
the testis was exposed through an incision. Bilateral 
testicular biopsies from the upper, middle, and lower 
poles were performed. Microdissection TESE, which 
involved identification of spermatogenically active 
areas under high magnification for more targeted 
biopsies, was performed starting from 2010. The 
biopsied testicular tissue was minced mechanically 
with two microscope slides, and incubated for 1 
hour to allow the sperms to swim out of the tissue. 
Enzymatic digestion of the testicular tissue was 
performed as described when no sperms were seen 
under microscope.20 The testicular sperms were 
isolated by mini-density gradient centrifugation. 
Sperms with high density at the bottom of the 
gradient as well as those in the interface between the 
gradients were collected in two aliquots of culture 
medium. Before ICSI, the embryologist searched the 
sperms first in the whole aliquot containing sperms 
of high density, and then in the aliquot containing 
sperms at the interface if no sperm was found in 
the first aliquot. Spare sperms were cryopreserved. 
Fertilisation was achieved by ICSI in patients with 
successful sperm retrieval. One or two embryos 
were replaced 2 days after retrieval. Luteal phase 
support was given with either two doses of hCG 
1500 IU 5 days apart or vaginal progesterone for 2 
weeks after embryo transfer. Patients were followed 
up with a urinary pregnancy test 16 days after 
embryo transfer and those with a positive pregnancy 
test had transvaginal ultrasound scan performed 10 
to 14 days later and were referred for antenatal care 
at 8 to 10 weeks of gestation. Pregnancy outcome 
was monitored. Pregnancy was defined as a positive 
urinary pregnancy test. A clinical pregnancy was 
defined as a pregnancy with the presence of one or 
more intrauterine sac on transvaginal ultrasound. 
An ongoing pregnancy was defined as the presence 
of at least one fetal heart pulsation on ultrasound 
beyond 20 weeks. When no sperms were retrieved, 
the collected oocytes were either discarded, donated, 
or frozen if further treatment with donor sperm was 
considered.
 Data analyses were performed by the Statistical 
Package for the Social Sciences (Windows version 
20.0; SPSS Inc, Chicago [IL], US). Comparisons 
between the groups were made using the Fisher’s 
exact test, and P<0.05 was considered statistically 
significant.
Results
Only information from the first cycle of IVF-
TESE was included. Of 112 men who underwent 
TESE during the study period, 23 were excluded 
from analysis because of non-motile sperms in the 
ejaculate (n=3), ejaculatory dysfunction (n=4), and 
obstructive azoospermia and underwent TESE after 
failed microepididymal sperm aspiration (n=16). 
Therefore, 89 patients with NOA were included in 
the analysis.
 The mean age of the men was 37.2 (standard 
deviation [SD], 6.2) years. Of the 85 patients with 
smoking history available, 59 (69.4%) were non-
smokers and 26 (30.6%) were smokers. Genetic 
information was missing in nine men. Of 76 men 
with genetic information available, eight (10.5%) had 
karyotypic abnormality—six were sex chromosomal 
and two were autosomal, as shown in Table 1. The 
most common sex chromosomal abnormality was 
Klinefelter syndrome (3/6, 50%; 1 non-mosaic and 2 
mosaic). The two men with autosomal chromosome 
abnormality were a ring chromosome 21 and a 
mosaic supernumerary marker chromosome. Of 
these 76 men, nine (11.8%) had microdeletion of the 
Y chromosome. The most common Y-microdeletion 
was AZFc microdeletion (6/9, 66.7%). Three 
men had both chromosomal abnormality and Y-
microdeletion.
 Of the 89 patients, sperms were successfully 
retrieved in 40 (44.9%). There was no statistically 
significant difference in the sperm retrieval rate 
in those with karyotype abnormalities and AFZc 
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microdeletion compared with those without (Table 2). 
The same was true when those with sex chromosomal 
abnormality were compared with those having 
normal karyotype. Sperms were retrieved in the two 
patients with mosaic Klinefelter syndrome but not 
the one with non-mosaic Klinefelter syndrome. For 
those with Y-microdeletion, sperms were retrieved 
in 50% (3/6) with AZFc microdeletions, but no 
sperms were found in the men with AZFa+b+c and 
AZFb+c microdeletions. The men with AZFa+b+c 
and AZFb+c microdeletions all had co-existing sex 
chromosomal abnormalities (Table 1).
 The mean age of the female partners was 37.2 
(SD, 6.2) years. The median dosage of gonadotropins 
used was 1950 IU (interquartile range, 1650-2550 
IU), duration of stimulation 12 days (11-14 days), 
peak oestradiol level 11 341 pmol/L (7859.5-19 260.5 
pmol/L), and the number of metaphase II oocytes 
obtained was 8 (4-13). Pregnancy test was positive 
in 15/89 (16.9%) and the clinical pregnancy rate was 
12/89 (13.5%). Among those with sperms found, 
pregnancy test was positive in 15/40 (37.5%) and the 
clinical pregnancy rate was 12/40 (30.0%). Clinical 
pregnancy rate per transfer was 12/35 (34.3%). Two 
patients had biochemical pregnancy and one had 
ectopic pregnancy. There were 10 live births—seven 
singletons and three pairs of twins. One patient 
underwent second-trimester medical termination 
of pregnancy for fetal alobar holoprosencephaly. 
One had an ongoing pregnancy at 12 weeks but 
was subsequently lost to follow-up. The ongoing 
pregnancy rate per cycle was 10/89 (11.2%). The 
clinical pregnancy rate was not statistically different 
between those who had karyotypic abnormalities 
(0/5, 0% vs 8/61, 13.1%; P=1.000) and Y-microdeletion 
(1/6, 16.7% vs 8/61, 13.1%; P=1.000) compared with 
those who did not. Among the five patients who did 
not have embryo transfer, two had failed fertilisation, 
two had no transferrable embryos, and one had no 
oocyte retrieved. 
TABLE 1.  Success of TESE and pregnancy outcome in patients with genetic abnormality
Patient 
No.
Karyotypic abnormality Y-microdeletion Presence of 
sperms
Outcome of fertilisation (normal 
fertilisation/metaphase II)
Pregnancy
1 47XXY - - N/A -
2 47,XXY/46,X (29:1) - + 1/3 (33.3%) -
3 46XY/47XXY (29:1) - + 9/15 (60.0%) -
4 46XY/45X (33:1) AZFb+c - N/A -
5 46,X,der(Y).ish i(Y)(p10)(pter++,SRY++) AZFa+b+c - N/A -
6 45,X/46,X,idic(Y)(q11.2) (12:18) AZFb+c - N/A -
7 46,XY,r(21) - - N/A -
8 47,XY,+mar/46,XY - - N/A -
9 - AZFc - N/A -
10 - AZFc - N/A -
11 - AZFc - N/A -
12 - AZFc + 9/15 (60.0%) -
13 - AZFc + 1/13 (7.7%) +
14 - AZFc + 1/2 (50.0%) -
Abbreviations: N/A = not applicable; TESE = testicular sperm extraction; + = positive; - = negative
TABLE 2.  The relationship between Y-microdeletion and karyotypic abnormalities and success of testicular sperm extraction
No sperms Presence of sperms P value
AZFc microdeletion 3/6 (50.0%) 3/6 (50.0%) 1.000
No Y-microdeletion 33/61 (54.1%) 28/61 (45.9%) -
Karyotype abnormalities (any) 3/5 (60.0%) 2/5 (40.0%) 1.000
Normal karyotype 33/61 (54.1%) 28/61 (45.9%) -
Sex chromosomal abnormalities 1/3 (33.3%) 2/3 (66.7%) 0.596
Normal karyotype 33/61 (54.1%) 28/61 (45.9%) -
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Discussion
Ho et al17 highlighted the importance of male 
factor in infertility assessment and treatment in a 
recent case series in a local male infertility clinic. 
The incidence of azoospermia was reported to be 
up to 36.2%, of which 52.1% had a non-obstructive 
cause and would require TESE.17 With increasing 
awareness of male infertility, it is hoped that more 
men will seek professional help and share the burden 
in fertility treatment. Nevertheless, existing data 
available in the literature on outcomes of IVF-TESE 
are fragmentary5 and local data are still lacking. 
 Karyotypic abnormalities and Y-microdeletion 
have been associated with severe male factor 
infertility. Fu et al21 demonstrated high rates of 
chromosomal abnormalities and Y chromosome 
microdeletions in Chinese infertile men with 
azoospermia or severe oligozoospermia. In another 
local study from our centre, the prevalence of 
chromosomal abnormality and Y-microdeletion 
were up to 21.1% and 8.5%, respectively in the 
azoospermic group.6 The prevalence of sex 
chromosomal abnormality and Y-microdeletion in 
the present study was 6/76 (7.9%) and 9/76 (11.8%), 
respectively; the former was lower than that reported 
by our centre previously. This may be because 
we only included men who had TESE performed 
in the current study, and it is possible that some 
men, particularly those who were found to have 
genetic abnormality, did not further pursue assisted 
reproductive treatment considering the anticipated 
poor prognosis.
 Testing for chromosomal abnormalities 
and Y-microdeletion are recommended as an 
essential part of the workup of men with NOA or 
severe oligospermia by the American Society for 
Reproductive Medicine,13 American Urological 
Association,12 Canadian Urological Association,11 
and International Federation of Fertility Societies 
guidelines.14 In particular, microdeletion of the 
AZFa or AZFb regions were associated with poor 
prognosis of sperm retrieval and no sperms have 
been retrieved in these patients.22 Although our 
study did not show any statistically significant 
difference in the sperm retrieval rates in those 
with karyotype abnormalities and Y-microdeletion 
compared with those without, it should be noted 
that all patients who had sperms retrieved were 
having AZFc microdeletion consistent with existing 
reports, and those who had AZFabc and AZFbc did 
not have sperms retrieved. Nonetheless the three 
men with AZFabc and AZFbc microdeletions all 
had co-existing sex chromosomal abnormalities that 
may also have affected spermatogenesis. Men with 
AZFa or AZFb microdeletion are therefore often 
advised against TESE because of a very low chance 
of successful retrieval of mature spermatozoa. Given 
proper counselling, these patients may opt not to 
pursue further assisted reproductive techniques, and 
go directly for options including donor insemination 
or adoption. On the other hand, the majority of 
men with AZFc microdeletion have sperm available 
for use. In some studies, AZFc deletion was even 
associated with an increased likelihood of sperm 
retrieval.22 The sperm retrieval rate in men with 
Klinefelter syndrome via microdissection TESE 
has also been reported to be similar or even higher 
than in those with NOA and normal karyotype.23-25 
In our experience, sperms were only found in the 
two patients with mosaic Klinefelter syndrome but 
not the one with non-mosaic Klinefelter syndrome. 
Previous studies showed that sperms are more likely 
to be retrieved in younger men with Klinefelter 
syndrome.26,27 In our study, the man with non-
mosaic Klinefelter syndrome was 42 years old and 
might have passed the window of opportunity for 
successful sperm retrieval. The two patients with 
mosaic Klinefelter syndrome were 34 and 47 years 
old, respectively. 
 This study provides important information 
on the prognosis for men with NOA. The sperm 
retrieval rate of 44.9% is very similar to a previous 
report at our centre where sperms were found in 
12/26 (46.2%) of men.28 In that study, the pregnancy 
rate was 14.3% per cycle when spermatozoa were 
injected. Our study showed that the chance for a 
man with NOA undergoing TESE to father his own 
child is 13.5%, very similar to that of 13.4% reported 
by Vloeberghs et al.5 Indeed, Vloeberghs et al5 have 
only included men with normal karyotype and 
absence of Y-microdeletion, who were included in 
our study, and we only included men who underwent 
first cycle of IVF-TESE. The clinical pregnancy rate 
would have been higher if we also included men who 
underwent further attempts. Nonetheless, men were 
generally advised against further TESE after failure 
to retrieve sperms in the first attempt owing to the 
poor prognosis.
 Another important issue is the potential for the 
genetic abnormality to be transmitted vertically via 
assisted reproductive technology. Couples wherein 
the male partner has Y-microdeletion should be 
counselled about the potential for inheritance of 
compromised fertility by male offspring and proper 
genetic counselling should be in place before 
embarking on IVF-TESE. 
 The practice of our centre was synchronous 
TESE on the day of oocyte retrieval. Several studies 
have shown comparable fertilisation and pregnancy 
rates when TESE is performed beforehand, either 
on the day before oocyte retrieval29 or even prior to 
initiation of controlled ovarian hyperstimulation.30 
The merit of the latter approach is that women do not 
have to go through controlled ovarian stimulation if 
no sperms can be retrieved, and therefore can avoid 
the risks of ovarian hyperstimulation syndrome and 
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the costs involved. The available cryopreservation-
thawing procedure for sperms leads to sperm loss 
however, and there is still a possibility that the cycle 
will have to be cancelled if there are no viable sperms 
after thawing. 
 As 50% of couples undergo IVF-TESE in 
vain, with resulting psychological and financial 
implications, research into various factors that could 
predict successful sperm retrieval is important. 
Previous findings from our retrospective study did 
not suggest any significant differences in the age, 
history of mumps or orchitis/oligozoospermia, 
volume of both testes, serum FSH and testosterone 
levels in men with or without spermatozoa in IVF-
TESE cycles.28 Indeed, no individual biochemical 
or hormonal marker has been found to reliably 
predict success in TESE.31 Although histopathology 
of testicular biopsy has been shown to predict TESE 
outcome, it is invasive and usually done at the time of 
TESE itself rather than beforehand in many patients, 
limiting its role as a predictive marker.31 The detection 
of Y chromosome microdeletion, especially AZFa 
and AZFb, was important to guide prognosis as 
discussed above. Ramasamy et al32 showed that high 
serum FSH level in men did not affect the success 
of microdissection TESE and should not be used to 
deny men the possibility to father a child with their 
own genetic material.14 Similarly, testicular size may 
represent poor spermatogenesis in general but does 
not consistently predict sperm retrieval rate.31 In 
a meta-analysis, serum inhibin B had a sensitivity 
of 0.65 and a specificity of 0.83 in prediction of 
successful TESE but it was still suboptimal as a 
single predictive criterion.33 Seminal anti-Müllerian 
hormone and inhibin B are secreted by the Sertoli 
cells into the seminiferous tubules and therefore in 
theory are more direct markers of spermatogenesis, 
but their predictive value for successful TESE was 
not confirmed in a prospective study of 139 men with 
NOA by Mitchell et al.34 A combination of factors 
have been shown to fare better, and authors have 
described the use of a predictive score involving the 
total testicular volume, FSH, and inhibin B to predict 
the sperm retrieval rate in NOA.35
 There are several limitations to our study. 
The number of men who declined genetic testing 
or TESE was not known. These men may be those 
with anticipated poor prognosis such that our study 
has included those with ‘better’ prognosis and 
therefore a higher sperm retrieval rate. In addition, 
while some authors suggest that hormonal profile 
or testicular volume may have provided prognostic 
information,35,36 our information on hormonal profile 
of men was incomplete. Prior to TESE, FSH might 
have been checked up to 2 years because of the long 
waiting list for IVF, and therefore was not analysed 
in this study. Other important limitations are the 
small number of cases and retrospective nature of 
our study that precludes proper statistical analysis. 
When pregnancy outcome is analysed, it is essential 
to remember the other confounding variables of the 
female partner such as age and diagnostic category 
that limit the conclusions that can be drawn. 
Moreover, as the study spanned over 13 years, there 
have been changes such as surgical techniques. Men 
included in the earlier years underwent TESE while 
those more recently underwent microdissection 
TESE. Further studies looking into different 
prognostic factors to predict successful sperm 
retrieval are needed. 
Conclusions
The sperm retrieval rate and clinical pregnancy 
rate per cycle in men undergoing IVF-ICSI-TESE 
in our unit were 44.9% and 13.5%, respectively. 
Karyotype and AZFc microdeletion abnormalities 
did not predict the success of sperm retrieval or 
clinical pregnancy rate in couples undergoing 
IVF-ICSI-TESE in the present case series, but are 
important in patient counselling. Consistent with 
existing literature, no sperms could be retrieved in 
individuals with AZFa and AZFb microdeletions.
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